Inflammatory bowel disease (IBD) is characterized by destructive inflammation of the intestinal tract with ulcerative colitis and Crohn’s disease as the most common disorders. Both diseases are life-long with periods of remission and relapse.1
The EliA™ IBD portfolio, comprising the EliA Calprotectin 2 and the EliA™ ASCA IgA and IgG tests (ASCA: anti-Saccharomyces cerevisiae antibodies), supports the identification and differentiation of IBD.
The follow-up of a positive EliA Calprotectin 2 test result with EliA ASCA IgA and IgG tests and a p-ANCA indirect immunofluorescence assay (IFA) helps differentiate between Crohn’s disease and ulcerative colitis, potentially avoiding further investigations and providing guidance for endoscopic procedures.9,10
The high sensitivity (98-99%) of the EliA Calprotectin 2 test, together with a negative predictive value (NPV) of 98.4 percent, make the test an outstanding tool helping to rule out inflammatory bowel disease.7,8
The EliA™ gastrointestinal portfolio* enables you to help rule in or rule out IBD (and subsequently differentiate between Crohn’s disease and ulcerative colitis), IBS, celiac disease, non-celiac gluten sensitivity, and wheat allergy.
The EliA gastrointestinal portfolio can be measured from one sample in one run and on the same fully automated Phadia™ Laboratory Systems.
*EliA Calprotectin 2, EliA ASCA IgA and IgG, EliATM Celikey IgA and IgG, EliATM GliadinDP IgA and IgG tests, ImmunoCAP™ Wheat allergen, f4